StoneX Group’s Anavex Life Sciences AVXL Stock Holding History

StoneX Group’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,893	Closed	-$119K	–	362
2023 Q1	$119K	Buy	+13,893	New	+$139K	0.07%	308

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $1.74B AUM 32.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

StoneX Group's AVXL Position: Q2 2023 in Review

StoneX Group sold out of Anavex Life Sciences (AVXL) in Q2 2023, closing a stake of 13,893 shares — an estimated $119K sold.

StoneX Group first reported a position in AVXL in Q1 2023 and held it in 1 quarter. The position peaked at $119K in Q1 2023. 144 funds tracked by Wall St. Rank hold AVXL as of Q2 2023.

StoneX Group reported no remaining Anavex Life Sciences position as of Q2 2023 after selling out during the quarter.
StoneX Group sold 13,893 Anavex Life Sciences shares in Q2 2023, an estimated $119K.
StoneX Group first reported a position in Anavex Life Sciences in Q1 2023 and held it in 1 quarter.
StoneX Group's Anavex Life Sciences position peaked at $119K in Q1 2023.
144 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2023.

Based on StoneX Group's 13F filing for Q2 2023, filed 14 Aug 2023.